AT-101, the R-(-) enantiomer of Gossypol acetic acid, binds to Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 μM, 0.48 μM and 0.18 μM; no Inhibits the BIR3 domain and BID. Phase 2.
AT-101 inhibits a diverse panel of lymphoproliferative malignancies with IC50 of 1.2 μM to 7.4 μM after 24 hours of treatment, 0.7 μM to 3.9 μM after 48 hours of treatment, IC50 of 72 hours after treatment 0.3 μM to 1.7 μM. AT-101 (10 μM) disrupts mitochondrial membrane potential (Δψm) in a concentration- and time-dependent manner in diffuse large B-cell and mantle cell lymphoma cell lines.
AT-101 treated SCID beige mice bearing RL-DLBCL xenografts, it was still detectable in plasma, with a mean concentration of 0.49 μM in the 35 mg/kg group and 0.39 μM in the 200 mg/kg group . In SCID beige mice treated with it, peak plasma concentrations were observed after 30 minutes, and the mean plasma concentration in the 200 mg/kg group was almost 4-fold higher than that in the 35 mg/kg group (7.88 μM and 27.78 μM, respectively).
| Target | Value |
Mcl-1
(Cell-free assay) | 0.18 μM(Ki) |
Bcl-2
(Cell-free assay) | 0.32 μM(Ki) | td>
Bcl-xL
(Cell-free assay) | 0.48 μM(Ki) |
